Advertisement
CANF vs NCEL
Which Stock Would AI Choose? Can-Fite BioPharma Ltd. (CANF) vs. NewcelX Ltd. (NCEL) Stock Comparison
Key Takeaways
- CANF is a later-stage, Israel-based biopharmaceutical company advancing oral small-molecule drug candidates in oncology and inflammatory disease, while NCEL is an earlier-stage, Switzerland-based developer of stem-cell-derived cell therapies focused on diabetes.
- Both names are pre-revenue, clinical-stage biotech companies with small market capitalizations, meaning elevated risk and reliance on clinical and financing catalysts.
- Tickeron AI Verdict: On observable factors such as pipeline maturity, catalyst density, and trend consistency, CANF currently holds the relative edge over NCEL.
- You can dig deeper into each ticker's CANF Major News and CANF Today's Price Move, as well as NCEL Major News and NCEL Today's Price Move, on their dedicated pages.
- To see how AI trading systems are positioning across the market, explore the curated Trending AI Robots page.
Introduction
Investors screening small-cap biotechnology often weigh pipeline maturity, clinical catalysts, and financing risk when deciding where to allocate capital. This stock comparison examines two such companies: Can-Fite BioPharma Ltd. (CANF), a developer of oral small-molecule therapies for cancer and inflammatory conditions, and NewcelX Ltd. (NCEL), a developer of stem-cell-derived cell therapies for diabetes. Both are pre-revenue and carry the elevated volatility typical of clinical-stage biotech, yet their relative performance and market positioning have diverged in recent weeks. This analysis is most relevant to growth-oriented traders and long-term investors comfortable with binary clinical outcomes and early-stage development risk.
CANF Overview and Recent Performance
Can-Fite BioPharma Ltd. (CANF) is a clinical-stage biopharmaceutical company headquartered in Israel. Its platform targets the A3 adenosine receptor (A3AR), and its pipeline includes Piclidenoson for psoriasis and Namodenoson for liver cancer and pancreatic cancer, among other indications. Several programs hold regulatory designations such as FDA Fast Track and orphan drug status.
In recent market activity, CANF has traded at a low single-digit share price, reflecting a micro-cap valuation and a meaningful pullback from its 52-week high. Sentiment has been shaped by a mix of clinical and financing events. The company presented final positive Phase IIa data for Namodenoson in advanced pancreatic cancer, reported longer-than-anticipated overall survival trends in its pivotal Phase III liver cancer study, and completed enrollment for a psoriasis interim analysis. These catalysts have been partially offset by dilution concerns after a warrant exercise that raised roughly $4 million, and by the lingering technical effects of a prior reverse stock split. Net-net, the stock's relative performance has been pressured, even as the underlying clinical narrative has strengthened.
NCEL Overview and Recent Performance
NewcelX Ltd. (NCEL) is a biopharmaceutical company based in Switzerland developing transformative stem-cell-derived therapies. Its lead candidate, NCEL-101, is an enriched pancreatic islet-like cluster product being developed for Type 1 diabetes and insulin-dependent Type 2 diabetes, alongside earlier-stage programs such as AstroRx for amyotrophic lateral sclerosis (ALS) and a small-molecule orexin platform.
In recent weeks, NCEL has also traded at a low single-digit share price with a small market capitalization. Positive developments have included the completion of a successful FDA Pre-IND (pre-Investigational New Drug) meeting, which provided a clearer regulatory pathway toward clinical trials, a patent grant in Brazil protecting its cell-selection technology, and the appointment of a prominent diabetes researcher to its scientific advisory board. The company also completed a small equity financing priced at a premium, signaling some investor confidence. At the same time, NCEL remains at an earlier clinical stage than CANF, with its lead program not yet in human trials, which contributes to a wider range of potential outcomes and thinner trading liquidity.
Trending AI Robots
Tickeron's Trending AI Robots page curates a selection of AI-driven trading bots from a broader universe of hundreds of automated systems that trade thousands of different tickers. Because market conditions shift constantly, only the bots best suited to the current environment earn a place in this featured section. Each bot operates with its own trading style, strategy, timeframe, performance record, and set of tickers, so the collection spans everything from short-term momentum approaches to longer-horizon trend systems. For traders comparing names like CANF and NCEL, reviewing these bots can offer a data-driven view of how automated systems are currently positioned. Explore the Trending AI Robots page to see which strategies are leading the market today.
Head-to-Head Comparison
The clearest contrast between these two stocks is pipeline stage and therapeutic focus. CANF operates a diversified, oral small-molecule platform with multiple Phase III programs already underway, giving it nearer-term data catalysts across oncology and inflammatory disease. NCEL is concentrated on a cell-therapy approach for diabetes that is still approaching first-in-human trials, offering a potentially large addressable market but fewer immediate clinical readouts.
Their risk profiles also differ. CANF has leaned on warrant exercises and discounted equity raises, creating dilution pressure that has weighed on share price despite positive clinical news. NCEL recently completed a small premium financing, but its earlier stage and low float contribute to higher volatility and wider bid-ask spreads. In terms of market sentiment, CANF has benefited from analyst upgrades and a reaffirmed Buy rating with a higher price target, while NCEL has drawn an initiation at Buy with a significantly higher long-term target, though with far less analyst coverage overall. Sector exposure is similar in that both are healthcare/biotech, but CANF's oral drug profile carries different manufacturing and regulatory risk than NCEL's cell-therapy model.
Tickeron AI Verdict
Based on observable factors such as pipeline maturity, catalyst frequency, and trend consistency, Tickeron's AI framework would likely favor CANF over NCEL in the current environment. CANF presents a more advanced clinical position with multiple Phase III programs and a steady stream of near-term data events, which tends to support a more consistent, data-rich trading signal. NCEL offers a compelling but earlier-stage narrative whose outcomes are further out on the horizon. This assessment is probabilistic rather than definitive, reflecting the inherent uncertainty of clinical-stage biotech investing and the possibility that either name could re-rate quickly on new information.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CANF is a Hold and NCEL is a Hold.
CANF's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for CANF turned positive on November 02, 2026. Looking at past instances where CANF's MACD turned positive, the stock continued to rise in 31 of 39 cases over the following month. The odds of a continued upward trend are 79%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CANF's RSI Oscillator exited the oversold zone, 35 of 47 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 54 of 71 cases where CANF's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Momentum Indicator moved above the 0 level on November 10, 2026. You may want to consider a long position or call options on CANF as a result. In 62 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 70%.
Following a +5.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where CANF advanced for three days, in 153 of 198 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
CANF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CANF declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for CANF entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 54 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.715) is normal, around the industry mean (3.498). P/E Ratio (-0.349) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (8.621) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. CANF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CANF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
NCEL's Stochastic Oscillator is sitting in overbought zone for 1 day
Expect a price pull-back in the near future.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 50-day moving average for NCEL moved below the 200-day moving average on October 23, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NCEL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
NCEL broke above its upper Bollinger Band on November 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for NCEL entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NCEL's RSI Oscillator exited the oversold zone, 33 of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Momentum Indicator moved above the 0 level on November 05, 2026. You may want to consider a long position or call options on NCEL as a result. In 77 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 88%.
The Moving Average Convergence Divergence (MACD) for NCEL just turned positive on November 03, 2026. Looking at past instances where NCEL's MACD turned positive, the stock continued to rise in 31 of 38 cases over the following month. The odds of a continued upward trend are 82%.
Following a +11.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where NCEL advanced for three days, in 186 of 222 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 71 (best 1 - 100 worst), indicating slightly worse than average price growth. NCEL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.640) is normal, around the industry mean (3.498). P/E Ratio (4.929) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 80 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NCEL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
CANF | ||
|---|---|---|
OUTLOOK RATING 1..100 | 2 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 54 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 100 | |
PRICE GROWTH RATING 1..100 | 86 | |
P/E GROWTH RATING 1..100 | 9 | |
SEASONALITY SCORE 1..100 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| CANF | NCEL | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 74% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 76% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 70% | 2 days ago 88% |
| MACD ODDS (%) | 2 days ago 79% | 2 days ago 82% |
| TrendWeek ODDS (%) | 2 days ago 78% | 2 days ago 84% |
| TrendMonth ODDS (%) | 2 days ago 86% | 2 days ago 90% |
| Advances ODDS (%) | 3 days ago 77% | 22 days ago 84% |
| Declines ODDS (%) | 16 days ago 87% | 3 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 76% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 88% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CANF’s FA Score shows that 1 FA rating(s) are green while NCEL’s FA Score has 0 green FA rating(s).
- CANF’s FA Score: 1 green, 4 red.
- NCEL’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CANF’s TA Score shows that 6 TA indicator(s) are bullish while NCEL’s TA Score has 4 bullish TA indicator(s).
- CANF’s TA Score: 6 bullish, 2 bearish.
- NCEL’s TA Score: 4 bullish, 5 bearish.
Price Growth
CANF (@Biotechnology) experienced а +2.47% price change this week, while NCEL (@Biotechnology) price change was +8.33% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.76%. For the same industry, the average monthly price growth was -2.90%, and the average quarterly price growth was -13.48%.
Industries' Descriptions
@Biotechnology (+4.76% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
CANF and
Correlation & Price change
A.I.dvisor indicates that over the last year, CANF has been closely correlated with GNPX. These tickers have moved in lockstep 93% of the time. This A.I.-generated data suggests there is a high statistical probability that if CANF jumps, then GNPX could also see price increases.
| Ticker / NAME | Correlation To CANF | 1D Price Change % | ||
|---|---|---|---|---|
| CANF | 100% | -1.19% | ||
| GNPX - CANF | 93% Closely correlated | +1.46% | ||
| ICU - CANF | 91% Closely correlated | -3.06% | ||
| MLEC - CANF | 89% Closely correlated | N/A | ||
| LONA - CANF | 78% Closely correlated | -10.07% | ||
| NCEL - CANF | 62% Loosely correlated | +4.00% | ||
More | ||||
NCEL and
Correlation & Price change
A.I.dvisor indicates that over the last year, NCEL has been loosely correlated with APVO. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if NCEL jumps, then APVO could also see price increases.
| Ticker / NAME | Correlation To NCEL | 1D Price Change % | ||
|---|---|---|---|---|
| NCEL | 100% | +4.00% | ||
| APVO - NCEL | 63% Loosely correlated | -4.42% | ||
| CANF - NCEL | 62% Loosely correlated | -1.19% | ||
| MLEC - NCEL | 58% Loosely correlated | N/A | ||
| IRON - NCEL | 54% Loosely correlated | +4.16% | ||
| RANI - NCEL | 46% Loosely correlated | -2.47% | ||
More | ||||